INTRODUCTION
The overall prevalence of hypercholesterolemia in the Spanish adult population has been estimated between 34% and 50% in recent studies [1] [2] [3] . The importance of this high prevalence is due to the association of high levels of serum cholesterol with cardiovascular disease (CVD), which has been well established [4, 5] . For instance, the occurrence of CV events in patients with familial hypercholesterolemia has been highlighted, with a prevalence of premature CVD (before 55 years of age in men and before 65 years of age in women) of 10%, in contrast to less than 3% in relatives without familial hypercholesterolemia [6] . The search strategies executed in each electronic public-access libraries are presented in Table S2 in the supplementary material.
The information gathered was manually cross-checked using the relevant references given in the publications included. To select the studies, titles and abstracts were first examined. After this, full text of selected manuscripts was reviewed. The selection criteria for publications were as follows:
Inclusion Criteria
Studies carried out in Spain and focused on lipid levels of patients belonging to one of the following groups: (a) heterozygous familial hypercholesterolemia (HeFH); (b) overt CVD including acute coronary syndrome (ACS), chronic coronary heart disease (CHD), ischemic stroke (IS) and peripheral arterial disease (PAD); (c) DM; or (d) high CV risk.
ACS was defined as acute myocardial infarction or unstable angina in the last 12 months. Chronic CHD refers to patients with ACS occurred longer than 12 months, or with stable angina or revascularization. Regarding CV risk, a SCORE risk assessment [5 (tables for countries with low CV risk) or equivalent was considered. Furthermore, according to the objectives described before, the studies had to include information on one of the following results: (a) prevalence of hypercholesterolemia; (b) rates of pharmacological treatment or (c) control of LDLc levels.
Exclusion Criteria
Manuscripts were discarded if any of the following conditions applied: (a) carried out outside Spain; (b) studies that did not include original patient data (i.e., reviews, editorials or letters); (c) studies that did not include human data; (d) studies with pediatric populations or (e) case reports.
Compliance with Ethics Guidelines
This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
A total of 1362 publications were retrieved from PubMed, 537 from the BVS and 560 from Medes (512 were duplicates so an initial pool of 1947 original manuscripts were identified for title and abstract review). Following the selection process, the full text of 264 manuscripts was reviewed, of which a total of 120 original papers were finally considered (Fig. 1) .
HeFH
In the study using data from the electronic database of the Spanish Familial (Table 1) .
Hypercholesterolemia in Secondary Prevention

ACS
In studies carried out among patients with ACS the prevalence of hypercholesterolemia was highly variable ranging from 45% to 80%
[15-31]. The proportion of ACS patients undergoing LLT ranged between 33% and 90%, but control levels were poor with only 14% of patients with LDLc levels\70 mg/dl and 
CHD
The prevalence of hypercholesterolemia in patients with chronic CHD was more uniform than that found in patients with ACS, according to the information collected, ranging from 64% 
Hypercholesterolemia in Primary Prevention
DM
In accordance with a previous diagnosis or the use of LLT, data indicated that between 50% LLT lipid-lowering treatment, FH familiar hypercholesterolemia, DM diabetes mellitus, LDLc low-density lipoprotein cholesterol, ACS acute coronary syndrome, CHD coronary heart disease, BMI body mass index Regarding the rates of LLT usage (Table 3 ; Fig. 3 ), between 45% and 90% of DM patients were using a LLT [26, 69, 70] . With respect to the lipid control achieved in this population, rates ranged from 40% to 50% in DM patients with no CVD history (LDLc goal \100 mg/dl), to only 15% in DM patients with a history of CVD (LDLc goal \70 mg/dl).
Patients with High CV Risk
Within this group of special interest in the prevention of CVD, between 30% and 60% had a specific diagnosis of hypercholesterolemia, LLT was used in 50% to 60% of these patients
[1], while control rates ranged from 35% to 65%, considering a LDLc target of \100 mg/dl [1, 72, 73] . Table 4 and Fig. 4 summarize these data. among those diagnosed with controlled hypercholesterolemia and, who are undergoing a lipid-lowering treatment, the increased risk of ischemic heart disease was not statistically significant [84] .
Due, in large part, to the information above, the use of lipid-lowering drugs in Spain has increased from 18.9 defined daily doses (DDD) per 1000 inhabitants per day (DDD/1000 inhabitants/day) in the year 2000 to 102.6 DDD/1000 inhabitants/day in the year 2012, an increase of 442% [86] . Statins are the most commonly used drugs (91.7 DDD/1000 inhabitants/day in 2012) representing 89.3% of all LLT, but also fibrates, bile-acid sequestrants, ezetimibe, and omega 3 fatty acids contributed during 2012 to LLT use [86] .
The increase in the use of LLT can be justified by 
